Badanie wpływu metforminy i kombinacji leków (colchicine, baricitinib, dolutegravir) na spowolnienie starzenia, ból i zapalenie u pacjentów z osteoartrozą kolana

Baseline Assessment

After joining the study, you will undergo an initial evaluation that includes a medical history review, a physical Examination of the knee, and collection of blood and urine samples.

The samples will be used to measure epigenetic age, inflammatory proteins, and markers related to osteoarthritis pain.

Start of medication regimen

You will begin taking two oral study drugs each day for the duration of the trial (approximately 12 months).

The prescribed medications are:

Tivicay 50 mg film‑coated tablet, taken once daily;

Metformin 2000 mg film‑coated tablet, taken as directed (typically divided into two doses per day);

Colchicine 0.5 mg tablet, taken once daily;

Olumiant 2 mg film‑coated tablet, taken once daily.

All tablets are taken by mouth with water.

Regular follow‑up visits

You will attend clinic visits approximately every four weeks.

During each visit, safety will be assessed, blood and urine will be collected again, and any adverse effects will be recorded.

The study staff will verify that the medication is being taken as prescribed.

Mid‑study Assessment

At about six months after starting the medication, a detailed evaluation similar to the baseline Assessment will be performed.

This includes repeat measurement of epigenetic age, inflammatory markers, and pain severity.

Final Assessment and study completion

At the end of the study period (around 12 months), you will undergo a final evaluation.

The same procedures as the baseline Assessment will be repeated to determine changes in biological age, inflammation, pain, and safety outcomes.

After the final visit, the study medication will be discontinued according to the protocol.